LifeMD (LFMD) said Tuesday that it plans to offer "broad, affordable, and streamlined" access to Novo Nordisk's (NVO) weight-loss drug Wegovy.
The company said all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or do not have weight-loss medication coverage through their insurance provider.
Shares of LifeMD surged 22% in early trading Tuesday.
Price: 7.47, Change: +1.37, Percent Change: +22.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.